To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF
Public ClinicalTrials.gov record NCT05483907. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Double-blind, Placebo-controlled, 24-Week Study to Evaluate the Efficacy, Safety, and Tolerability of BBT-877, as Mono- or add-on Therapy, in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, study to evaluate the efficacy, safety, and tolerability of 200 mg twice daily (BID) of BBT-877 in patients with IPF, with or without AF approved background therapies (pirfenidone or nintedanib).
Study identification
- NCT ID
- NCT05483907
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 129 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 11, 2023
- Primary completion
- Jan 25, 2025
- Completion
- Feb 22, 2025
- Last update posted
- Mar 31, 2025
2023 – 2025
United States locations
- U.S. sites
- 16
- U.S. states
- 10
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pulmonary Associates P.A. | Phoenix | Arizona | 85006-2611 | — |
| Southern Arizona VA Health Care System - NAVREF - PPDS | Tucson | Arizona | 85723-0001 | — |
| Keck Medical Center of USC | Los Angeles | California | 90033 | — |
| VA Palo Alto Health Care System | Palo Alto | California | 94304-1207 | — |
| National Jewish Health Main Campus | Denver | Colorado | 80206-2761 | — |
| St. Francis Medical Institute - Clinedge | Clearwater | Florida | 33765 | — |
| Renstar Medical Research | Ocala | Florida | 34470 | — |
| Central Florida Pulmonary Group PA | Orlando | Florida | 32803-5443 | — |
| Augusta University | Augusta | Georgia | 30912-0004 | — |
| Northwestern Memorial Hospital | Chicago | Illinois | 60611-2993 | — |
| Loyola University Medical Center | Maywood | Illinois | 60153-3328 | — |
| The Lung Research Center, LLC | Chesterfield | Missouri | 63017-3632 | — |
| Hannibal Regional Healthcare System-HRMG-Hannibal | Hannibal | Missouri | 63401-6890 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29425-8900 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37204 | — |
| Premier Pulmonary Critical Care & Sleep Medicine | Denison | Texas | 75020 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 28 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05483907, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 31, 2025 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05483907 live on ClinicalTrials.gov.